-
Contribution of Sub-Saharan African medicinal plants to cancer research: Scientific basis 2013–2023 Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-11 Marc D.W. Adico, Bagora Bayala, Julio Bunay, Silvère Baron, Jacques Simpore, Jean-Marc A. Lobaccaro
Cancer incidence and mortality rates are increasing worldwide. Cancer treatment remains a real challenge for African countries, especially in sub-Saharan Africa where funding and resources are very limited. High costs, side effects and drug resistance associated with cancer treatment have encouraged scientists to invest in research into new herbal cancer drugs. In order to identify potential anticancer
-
IUPHAR ECR review: Cancer-Related Anorexia-Cachexia in Cancer Patients: Pathophysiology and Treatment Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-09 Chowdhury Iftekhar Hossain, Rahman Shamima, Afroze Yeasmin Jahan, Shovah Sharmeen Tania
Cancer-related anorexia-cachexia (CRAC) comprises one of the most common syndromes of advanced cancer patients. The prevalence of CRAC increases from 50 to 80% before death. CRAC is associated not only with impaired quality of life in patients and family members but also with shorter survival. The management of CRAC is a great challenge in clinical practice. There are no definite practice guidelines
-
Corrigendum to “A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation” [Pharmacol. Res. 194 (2023) 106851] Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-08 Feiqiong Gao, Qigu Yao, Jiaqi Zhu, Wenyi Chen, Xudong Feng, Bing Feng, Jian Wu, Karel Pacak, Jared Rosenblum, Jiong Yu, Zhengping Zhuang, Hongcui Cao, Lanjuan Li
-
Corrigendum to ‘Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease’ [Pharmacol Res. 174 (2021) 105973] Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-08 Sudhir Kshirsagar, Neha Sawant, Hallie Morton, Arubala P. Reddy, P. Hemachandra Reddy
-
D-arabinose acts as antidepressant by activating the ACSS2-PPARγ/TFEB axis and CRTC1 transcription Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-07 Yaxin Guo, Nuo Chen, Ming Zhao, Baihui Cao, Faliang Zhu, Chun Guo, Yongyu Shi, Qun Wang, Yan Li, Lining Zhang
CREB-regulated transcription coactivator 1 (CRTC1), a pivotal synaptonuclear messenger, regulates synaptic plasticity and transmission to prevent depression. Despite exhaustive investigations into CRTC1 mRNA reductions in the depressed mice, the regulatory mechanisms governing its transcription remain elusive. Consequently, exploring rapid but non-toxic CRTC1 inducers at the transcriptional level is
-
Targeting aberrant glycosylation to modulate microglial response and improve cognition in models of Alzheimer’s disease Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-06 Yue Wang, Yixuan Du, Hongfei Huang, Yiming Cao, Kemeng Pan, Yueqian Zhou, Jiawei He, Wenbing Yao, Song Chen, Xiangdong Gao
Altered glycosylation profiles have been correlated with potential drug targets in various diseases, including Alzheimer’s disease (AD). In this area, the linkage between bisecting N-acetylglucosamine (GlcNAc), a product of N-acetylglucosaminyltransferase III (GnT-III), and AD has been recognized, however, our understanding of the cause and the causative role of this aberrant glycosylation in AD are
-
Beyond lectures and practical courses: Teaching pharmacology using imaginative pedagogical tools Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-04 J.E. Baños, E. Blanco-Reina, I. Bellido-Estévez, F. Bosch, M.R. Cabello, I. Cambra-Badii, J.P. De la Cruz, P. D’Ocón, M.D. Ivorra, M. Ferrándiz, J.A. González-Correa, E. Martín-Montañez, F. Martos, J. Pavía, E. Sanz
Pharmacology has broadened its scope considerably in recent decades. Initially, it was of interest to chemists, doctors and pharmacists. In recent years, however, it has been incorporated into the teaching of biologists, molecular biologists, biotechnologists, chemical engineers and many health professionals, among others. Traditional teaching methods, such as lectures or laboratory work, have been
-
peu-MIR2916-p3-enriched garlic exosomes ameliorate murine colitis by reshaping gut microbiota, especially by boosting the anti-colitic Bacteroides thetaiotaomicron – Correspondence Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-02 Xin-Zhi Huang, Chin-Yuan Yii, Su-Boon Yong, Chia-Jung Li
-
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-02 Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, Changchun Zeng
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, the occurrence of acquired resistance to EGFR-TKIs is an unavoidable outcome observed in these patients. Disruption of the PI3K/AKT/mTOR signaling pathway can contribute to the emergence of resistance
-
Vanillic acid restores homeostasis of intestinal epithelium in colitis through inhibiting CA9/STIM1-mediated ferroptosis Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-02 Jiahui Ni, Lijie Zhang, Guize Feng, Weilian Bao, Yirui Wang, Yuran Huang, Tongqing Chen, Jieli Chen, Xinyue Cao, Keyuan You, Sheng Tan, Thomas Efferth, Hong Li, Bo Li, Xiaoyan Shen, Yan You
The damage of integrated epithelial epithelium is a key pathogenic factor and closely associated with the recurrence of ulcerative colitis (UC). Here, we reported that vanillic acid (VA) exerted potent therapeutic effects on DSS-induced colitis by restoring intestinal epithelium homeostasis via the inhibition of ferroptosis. By the CETSA assay and DARTS assay, we identified carbonic anhydrase IX (CAIX
-
CircBIRC6 facilitates the malignant progression via miR-488/GRIN2D-mediated CAV1-autophagy signal axis in gastric cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-02 Zhiyuan Tang, Jieying Li, Bing Lu, Xiaojing Zhang, Lei Yang, Yue Qi, Sutian Jiang, Qianqian Wu, Yingjing Wang, Tong Cheng, Manyu Xu, Pingping Sun, Xudong Wang, Kai Miao, Han Wu, Jianfei Huang
Circular RNAs (circRNAs) represent a novel class of non-coding RNAs that play significant roles in tumorigenesis and tumor progression. High-throughput sequencing of gastric cancer (GC) tissues has identified circRNA BIRC6 (circBIRC6) as a potential circRNA derived from the BIRC6 gene, exhibiting significant upregulation in GC tissues. The expression of circBIRC6 is notably elevated in GC patients
-
FPR1: A critical gatekeeper of the heart and brain Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-02 Ziyin Zhangsun, Yushu Dong, Jiayou Tang, Zhenxiao Jin, Wangrui Lei, Changyu Wang, Ying Cheng, Baoying Wang, Yang Yang, Huadong Zhao
G protein-coupled receptors (GPCRs) are currently the most widely focused drug targets in the clinic, exerting their biological functions by binding to chemicals and activating a series of intracellular signaling pathways. Formyl-peptide receptor 1 (FPR1) has a typical seven-transmembrane structure of GPCRs and can be stimulated by a large number of endogenous or exogenous ligands with different chemical
-
CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-03-01 Qi Lv, Yishu Zhang, Wen Gao, Juan Wang, Yaowen Hu, Hongqiong Yang, Ying Xie, Yingshan Lv, Heyuan Zhang, Dapeng Wu, Lihong Hu, Junwei Wang
PD-1 blockade therapy has made great breakthroughs in treatment of multiple solid tumors. However, patients with microsatellite-stable (MSS) colorectal cancer (CRC) respond poorly to anti-PD-1 immunotherapy. Although CRC patients with microstatellite instability (MSI) or microsatellite instability-high (MSI-H) can benefit from PD-1 blockade therapy, there are still some problems such as tumor recurrence
-
CD39hi identifies an exhausted tumor-reactive CD8+ T cell population associated with tumor progression in human gastric cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-29 Yang Shen, Yuan Qiu, Zhen-quan Duan, Yu-xian Li, Ying Wang, Yuan-yuan Zhang, Bao-hang Zhu, Xiao-hong Yu, Xue-ling Tan, Weisan Chen, Yuan Zhuang, Quan-ming Zou, Dai-yuan Ma, Liu-sheng Peng
The ectonucleotidase CD39 has been regarded as a promising immune checkpoint in solid tumors. However, the expression of CD39 by tumor-infiltrating CD8 T cells as well as their potential roles and clinical implications in human gastric cancer (GC) remain largely unknown. Here, we found that GC-infiltrating CD8 T cells contained a fraction of CD39 cells that constituted about 6.6% of total CD8 T cells
-
Gut Clostridium sporogenes-derived indole propionic acid suppresses osteoclast formation by activating pregnane X receptor Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-29 Renpeng Peng, Chao Song, Shuangquan Gou, Haiyang Liu, Honglei Kang, Yimin Dong, Yong Xu, Peixuan Hu, Kaiyong Cai, Qian Feng, Hanfeng Guan, Feng Li
Bone homeostasis is maintained by osteoclast-mediated bone resorption and osteoblast-mediated bone formation. A dramatic decrease in estrogen levels in postmenopausal women leads to osteoclast overactivation, impaired bone homeostasis, and subsequent bone loss. Changes in the gut microbiome affect bone mineral density. However, the role of the gut microbiome in estrogen deficiency-induced bone loss
-
Biological activities, Molecular mechanisms, and Clinical application of Naringin in Metabolic syndrome Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-29 Jie Chen, Xiang Qin, Mengyao Chen, Tianzhu Chen, Zheng Chen, Beihui He
Metabolic syndrome has become major health problems in recent decades, and natural compounds receive considerable attention in the management of metabolic syndrome. Among them, naringin is abundant in citrus fruits and tomatoes. Many studies have investigated the therapeutic effects of naringin in metabolic syndrome. This review discusses in vitro and in vivo studies on naringin and implications for
-
Bioenergetic dysfunction in the pathogenesis of intervertebral disc degeneration Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-28 Chao Song, Peixuan Hu, Renpeng Peng, Feng Li, Zhong Fang, Yong Xu
Intervertebral disc (IVD) degeneration is a frequent cause of low back pain and is the most common cause of disability. Treatments for symptomatic IVD degeneration, including conservative treatments such as analgesics, physical therapy, anti-inflammatories and surgeries, are aimed at alleviating neurological symptoms. However, there are no effective treatments to prevent or delay IVD degeneration.
-
Functional significance of O-linked N-acetylglucosamine protein modification in regulating autophagy Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-28 Zhuang Zhu, Wenhao Ren, Shaoming Li, Ling Gao, Keqian Zhi
Autophagy is a core molecular pathway that preserves cellular and organismal homeostasis. Being susceptible to nutrient availability and stress, eukaryotic cells recycle or degrade internal components via membrane transport pathways to provide sustainable biological molecules and energy sources. The dysregulation of this highly conserved physiological process has been strongly linked to human disease
-
A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-27 Yongrui Hai, Renming Fan, Ting Zhao, Ruizhuo Lin, Junyan Zhuang, Aohua Deng, Shanshui Meng, Zhuang Hou, Gaofei Wei
Dihydroorotate dehydrogenase (DHODH)-mediated ferroptosis defense is a targetable vulnerability in cancer. Currently, only a few DHODH inhibitors have been utilized in clinical practice. To further enhance DHODH targeting, we introduced the mitochondrial targeting group triphenylphosphine (TPP) to brequinar (BRQ), a robust DHODH inhibitor, resulting in the creation of active molecule B2. This compound
-
Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-24 Hu Zhang, Chenlu Mu, Yu Gu, Fanyi Meng, Xiali Qin, Hailong Cao
Optimizing second-line biologic therapies for adult ulcerative colitis (UC) post first-line failure is essential. Compare second-line biologic therapy efficacy in adult UC patients with prior treatment failure. A comprehensive search of electronic databases up to May 2023 was conducted to assess second-line biologic therapy efficacy using a random effects model. Parameters analyzed included clinical
-
Targeting autophagy to counteract neuroinflammation: A novel antidepressant strategy Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-23 Hua Gan, Qingyu Ma, Wenzhi Hao, Nating Yang, Zhe-Sheng Chen, Lijuan Deng, Jiaxu Chen
Depression is a common disease that affects physical and mental health and imposes a considerable burden on afflicted individuals and their families worldwide. Depression is associated with a high rate of disability and suicide. It causes a severe decline in productivity and quality of life. Unfortunately, the pathophysiological mechanisms underlying depression have not been fully elucidated, and the
-
Unveiling the role of iPLA2β in neurodegeneration: From molecular mechanisms to advanced therapies Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-22 Jiabin Liu, Jieqiong Tan, Beisha Tang, Jifeng Guo
Calcium-independent phospholipase Aβ (iPLAβ), a member of the phospholipase A2 (PLA2s) superfamily, is encoded by the gene. Mutations in the gene have been identified as the primary cause of infantile neuroaxonal dystrophy (INAD) and, less commonly, as a contributor to Parkinson's disease (PD). Recent studies have revealed that iPLAβ deficiency leads to neuroinflammation, iron accumulation, mitochondrial
-
Maresins as novel anti-inflammatory actors and putative therapeutic targets in sepsis Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-20 Yan Sun, Shujun Sun, Pu Chen, Yan Dai, Dong Yang, Yun Lin, Lisha Yi
Sepsis, a complex clinical syndrome characterized by an exaggerated host response to infection, often necessitates hospitalization and intensive care unit admission. Delayed or inaccurate diagnosis of sepsis, coupled with suboptimal treatment strategies, can result in unfavorable outcomes, including mortality. Maresins, a newly discovered family of lipid mediators synthesized from docosahexaenoic acid
-
In vitro models for neuropathic pain phenotypic screening in brain therapeutics Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-19 A.L. Martínez, J. Brea, D. López, N. Cosme, M. Barro, X. Monroy, J. Burgueño, M. Merlos, M.I. Loza
The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview
-
Corrigendum to “Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury” [Pharmacol. Res. 123 (2017) 83–92] Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-17 Enrico Gugliandolo, Roberta Fusco, Flavia Biundo, Ramona D’Amico, Filippo Benedetto, Rosanna Di Paola, Salvatore Cuzzocrea
-
ACOX1 deficiency-induced lipid metabolic disorder facilitates chronic interstitial fibrosis development in renal allografts Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-16 Yang-He Zhang, Qingfei Meng, Dan Zhang, Hongxia Yang, Guangtao Li, Yuxiong Wang, Mingdi Liu, Nian Liu, Jinyu Yu, Si Liu, Honglan Zhou, Zhi-Xiang Xu, Yishu Wang
Chronic interstitial fibrosis presents a significant challenge to the long-term survival of transplanted kidneys. Our research has shown that reduced expression of acyl-coenzyme A oxidase 1 (ACOX1), which is the rate-limiting enzyme in the peroxisomal fatty acid β-oxidation pathway, contributes to the development of fibrosis in renal allografts. ACOX1 deficiency leads to lipid accumulation and excessive
-
An account on the history of pharmacology in Spain Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-14 Ana María Aldea-Perona, Jesús Flórez Beledo, Jesús Frías Iniesta, Antonio G. García, Juan Tamargo, Francisco Zaragozá
-
CDK12 inhibition upregulates ATG7 triggering autophagy via AKT/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-13 Zimei Wu, Wenxin Zhang, Lu Chen, Tianxiao Wang, Xinhai Wang, Huanying Shi, Liudi Zhang, Mingkang Zhong, Xiaojin Shi, Xiang Mao, Haifei Chen, Qunyi Li
As the world’s fourth most deadly cancer, colorectal cancer (CRC) still needed the novel therapeutic drugs and target urgently. Although cyclin-dependent kinase 12 (CDK12) has been shown to be implicated in the malignancy of several types of cancer, its functional role and mechanism in CRC remain largely unknown. Here, we found that suppression of CDK12 inhibited tumor growth in CRC by inducing apoptosis
-
Isothiocyanates in Medicine: A Comprehensive Review on Phenylethyl-, Allyl-, and Benzyl-Isothiocyanates Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-13 Cosima C. Hoch, Maria Shoykhet, Tobias Weiser, Lena Griesbaum, Julie Petry, Khouloud Hachani, Gabriele Multhoff, Ali Bashiri Dezfouli, Barbara Wollenberg
In recent years, isothiocyanates (ITCs), bioactive compounds primarily derived from vegetables and herbs, have gained significant attention within the biomedical field due to their versatile biological effects. This comprehensive review provides an in-depth exploration of the therapeutic potential and individual biological mechanisms of the three specific ITCs phenylethyl isothiocyanate (PEITC), allyl
-
Natural Products for Combating Multidrug Resistance in Cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-10 Ting Chen, Zhicheng Xiao, Xiaoyan Liu, Tingfang Wang, Yun Wang, Fei Ye, Juan Su, Xuan Yao, Liyan Xiong, Dong-Hua Yang
Cancer cells frequently develop resistance to chemotherapeutic therapies and targeted drugs, which has been a significant challenge in cancer management. With the growing advances in technologies in isolation and identification of natural products, the potential of natural products in combating cancer multidrug resistance has received substantial attention. Importantly, natural products can impact
-
Alternative splicing in cardiomyopathy insights Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-09 Concetta Schiano, Claudio Napoli
-
Novel nano-drug delivery system for natural products and their application Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-08 Li Huang, Xue-Hua Huang, Xi Yang, Jia-Qin Hu, Yi-Zhun Zhu, Pei-Yu Yan, Ying Xie
The development of natural products for potential new drugs faces obstacles such as unknown mechanisms, poor solubility, and limited bioavailability, which limit the broadened applicability of natural products. Therefore, there is a need for advanced pharmaceutical formulations of active compounds or natural products. In recent years, novel nano-drug delivery systems (NDDS) for natural products, including
-
Nanoparticles and siRNA: A new era in therapeutics? Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-07 María Dolores Pérez-Carrión, Inmaculada Posadas, Valentín Ceña
Since its discovery in 1998, the use of small interfering RNA (siRNA) has been increasing in biomedical studies because of its ability to very selectively inhibit the expression of any target gene. Thus, siRNAs can be used to generate therapeutic compounds for different diseases, including those that are currently ‘undruggable’. This has led siRNA-based therapeutic compounds to break into clinical
-
Combining choline bitartrate and vitamin B12 ameliorates cognitive impairment in hypertensive elders with cognitive frailty Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-07 Pasquale Mone, Valentina Trimarco, Urna Kansakar, Raffaele Izzo, Gaetano Santulli, Bruno Trimarco
-
The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-07 Claudia Ceci, Pedro Miguel Lacal, Maria Luisa Barbaccia, Nicola Biagio Mercuri, Grazia Graziani, Ada Ledonne
The vascular endothelial growth factors (VEGFs) and their cognate receptors (VEGFRs), besides their well-known involvement in physiological angiogenesis/lymphangiogenesis and in diseases associated to pathological vessel formation, play multifaceted functions in the central nervous system (CNS). In addition to shaping brain development, by controlling cerebral vasculogenesis and regulating neurogenesis
-
-
Single-cell and spatial transcriptomics reveals that PTPRG activates the m6A methyltransferase VIRMA to block mitophagy-mediated neuronal death in Alzheimer’s disease Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-06 Donghua Zou, Xiaohua Huang, Yating Lan, Mika Pan, Jieqiong Xie, Qi Huang, Jingyi Zeng, Chun Zou, Zifei Pei, Cuihua Zou, Yingwei Mao, Jiefeng Luo
Neuronal death is one of the key pathologies in Alzheimer's disease (AD). How neuronal death begins in AD is far from clear, so clarifying this process may help develop effective therapies. This study collected single-cell RNA sequencing data of 85 AD samples and 83 control samples, covering the prefrontal cortex, internal olfactory cortex, superior parietal lobe, superior frontal gyrus, caudal internal
-
Allosteric inhibitor of SHP2 enhances macrophage endocytosis and bacteria elimination by increasing caveolae activation and protects against bacterial sepsis Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-04 Tianliang Li, Bing Xu, Wenqian Li, Xiaotao Cheng, Wenjing Tantai, Haiyan Zheng, Liming Zhao, Nan Li, Chaofeng Han
-
Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1 Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-04 Li Tao, Xiangyu Xia, Shujing Kong, Tingye Wang, Fangtian Fan, Weimin Wang
-
Interleukin-18 in chronic pain: Focus on pathogenic mechanisms and potential therapeutic targets Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-29 Jie Ju, Zheng Li, Xiaoqian Jia, Xiaoling Peng, Jihong Wang, Feng Gao
-
Insights into the role of derailed endocytic trafficking pathway in cancer: From the perspective of cancer hallmarks Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-29 Hongjie Guo, Chen Zhou, Mingming Zheng, Jie Zhang, Honghai Wu, Qiaojun He, Ling Ding, Bo Yang
-
The dangerous “West Coast Swing” by hyperglycaemia and chronic stress in the mouse hippocampus: Role of kynurenine catabolism Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-30 Micaela Gliozzi, Anna Rita Coppoletta, Antonio Cardamone, Vincenzo Musolino, Cristina Carresi, Saverio Nucera, Stefano Ruga, Federica Scarano, Francesca Bosco, Lorenza Guarnieri, Roberta Macrì, Rocco Mollace, Catherine Belzung, Vincenzo Mollace
-
Biologics, theranostics, and personalized medicine in drug delivery systems Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-29 Matteo Puccetti, Marilena Pariano, Aurélie Schoubben, Stefano Giovagnoli, Maurizio Ricci
-
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-02 Silpa Gampala, Hye-ran Moon, Randall Wireman, Jacqueline Peil, Sonia Kiran, Dana K. Mitchell, Kylee Brewster, Henry Mang, Andi Masters, Christine Bach, Whitney Smith-Kinnamen, Emma H. Doud, Ratan Rai, Amber L. Mosley, Sara K. Quinney, D. Wade Clapp, Chafiq Hamdouchi, James Wikel, Chi Zhang, Bumsoo Han, Millie M. Georgiadis, Mark R. Kelley, Melissa L. Fishel
AP endonuclease-1/Redox factor-1 (APE1/Ref-1 or Ref-1) is a multifunctional protein that is overexpressed in most aggressive cancers and impacts various cancer cell signaling pathways. Ref-1′s redox activity plays a significant role in activating transcription factors (TFs) such as NFκB, HIF1α, STAT3 and AP-1, which are crucial contributors to the development of tumors and metastatic growth. Therefore
-
Novel rapid treatment options for adolescent depression Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-02 Sandra Ledesma-Corvi, Jordi Jornet-Plaza, Laura Gálvez-Melero, M. Julia García-Fuster
-
The therapeutic effects of saikosaponins on depression through the modulation of neuroplasticity: From molecular mechanisms to potential clinical applications Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-02 Shen Chen, Ke Wang, Hongzhan Wang, Yang Gao, Kexin Nie, Xinyue Jiang, Hao Su, Yueheng Tang, Fuer Lu, Hui Dong, Zhi Wang
-
Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies? Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-02 Lucia La Sala, Valentina Carlini, Caterina Conte, Maria Belen Macas-Granizo, Elham Afzalpour, Jimmy Martin-Delgado, Marco D’Anzeo, Roberto F.E. Pedretti, Angelo Naselli, Antonio E. Pontiroli, Riccardo Cappato
-
Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway Pharmacol. Res. (IF 9.3) Pub Date : 2024-02-01 Chen Shi, Cong Wang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Zhang, Shijun Li, Yu Zhang
-
A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-25 Ola Sobhy A. Elmeseiny, Heidi Kaastrup Müller
-
Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-26 Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo
-
New insights into nucleic acid sensor AIM2: The potential benefit in targeted therapy for cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-24 Jian Zhou Cui, Zhi Huan Chew, Lina H.K. Lim
-
New strategies for medications to treat substance use disorders Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-20 Ivan D. Montoya, Nora D. Volkow
-
MicrobeTCM: a comprehensive platform for the interactions of microbiota and traditional Chinese medicine Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-23 Yufeng Chen, Yu Shi, Chengbang Liang, Zhuochao Min, Qiqi Deng, Rui Yu, Jiani Zhang, Kexin Chang, Luyao Chen, Ke Yan, Chunxiang Wang, Yan Tan, Xu Wang, Jianxin Chen, Qian Hua
-
Mitigation of sciatica injury-induced neuropathic pain through active metabolites derived from medicinal plants Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-17 Abdul Nasir, Ome Kalsoom Afridi, Sami Ullah, Haroon Khan, Qian Bai
-
Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-15 Yuanzhi Liu, Linwei Zhang, Long Wang, Xiaoqin Tang, Shengli Wan, Qianqian Huang, Mei Ran, Hongping Shen, Yan Yang, Sawitree Chiampanichayakul, Singkome Tima, Songyot Anuchapreeda, Jianming Wu
-
Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-19 Juan Tamargo, Julián Villacastín, Ricardo Caballero, Eva Delpón
-
IUPHAR review: Navigating the role of preclinical models in pain research Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-15 Seyed Asaad Karimi, Fatama Tuz Zahra, Loren J. Martin
Chronic pain is a complex and challenging medical condition that affects millions of people worldwide. Understanding the underlying mechanisms of chronic pain is a key goal of preclinical pain research so that more effective treatment strategies can be developed. In this review, we explore nociception, pain, and the multifaceted factors that lead to chronic pain by focusing on preclinical models. We
-
Agree to disagree: The contradiction between IL-18 and IL-37 reveals shared targets in cancer Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-17 Dongjie Wang, Bitian Zhang, Xiaolin Liu, Lea Ling-Yu Kan, Ping-Chung Leung, Chun-Kwok Wong
-
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-11 Robert Roskoski
-
Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy: Role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway Pharmacol. Res. (IF 9.3) Pub Date : 2024-01-11 Zhangwei Chen, Su Li, Muyin Liu, Ming Yin, Jinxiang Chen, Youran Li, Qiyu Li, You Zhou, Yan Xia, Ao Chen, Danbo Lu, Chenguang Li, Yuqiong Chen, Juying Qian, Junbo Ge